In vivo gene editing's recent clinical milestone is explored with upbeat analysis of its potential implications for genetic medicine and longevity.
Key Takeaways
- This is the first positive pivotal in vivo CRISPR Phase 3 clinical trial
- Treated patients experienced an 87% reduction in average monthly hereditary angioedema attacks
- No serious adverse events occurred and most side effects were mild or moderate